



9/ amdt A
RECEIVED
FEB 07 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

10/26/01
Date

David L. Parker

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Yang, et al.

Serial No.: 09/599,152

Filed: June 21, 2000

For: ETHYLENEDICYSSTEINE (EC)-DRUG
CONJUGATES, COMPOSITIONS AND
METHODS FOR TISSUE SPECIFIC
DISEASE IMAGING

Group Art Unit: 1645

Examiner: D. Jones

Atty. Dkt. No.: UTXC:664/DLP

RESPONSE TO RESTRICTION REQUIREMENT DATED SEPTEMBER 27, 2001

Commissioner for Patents
Washington, D.C. 20231

Commissioner:

This paper is submitted in response to the Restriction Requirement dated September 27, 2001 for which the date for response is October 27, 2001.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10020527/DLP.

Please enter the following amendments and consider the accompanying remarks.



1645

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

DAVID L. PARKER
PARTNER

INTERNET ADDRESS:
DPARKER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3055

RECEIVED

FEB 07 2002

TECH CENTER 1600/2900

FILE: UTXC:664

October 26, 2001

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
10/26/01 Date	 David L. Parker

Commissioner for Patents
Washington, DC 20231

RE: SN 09/599,152 "Ethylenedicysteine (EC)-Drug Conjugates, Compositions and Methods for Tissue Specific Disease Imaging" - Yang, et al. (UTXC:664)

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) A Response to Restriction Requirement dated September 27, 2001; and
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No. 50-1212/10020527/DLP.

Respectfully submitted,

David L. Parker
Reg. No. 32,165

DLP:lag
Encl.: As Noted